Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)Depreciation ExpenseEBIATOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

InMed Pharmaceuticals (INM) Long-Term Debt Repayments: 2021-2023

Historic Long-Term Debt Repayments for InMed Pharmaceuticals (INM) over the last 2 years, with Dec 2023 value amounting to $94,400.

  • InMed Pharmaceuticals' Long-Term Debt Repayments fell 12.76% to $94,400 in Q4 2023 from the same period last year, while for Dec 2023 it was $410,572, marking a year-over-year increase of 28.80%. This contributed to the annual value of $426,575 for FY2023, which is 24.78% up from last year.
  • InMed Pharmaceuticals' Long-Term Debt Repayments amounted to $94,400 in Q4 2023, which was down 4.37% from $98,709 recorded in Q3 2023.
  • Over the past 5 years, InMed Pharmaceuticals' Long-Term Debt Repayments peaked at $214,791 during Q4 2021, and registered a low of $17,411 during Q3 2021.
  • For the 3-year period, InMed Pharmaceuticals' Long-Term Debt Repayments averaged around $96,155, with its median value being $99,806 (2022).
  • Within the past 5 years, the most significant YoY rise in InMed Pharmaceuticals' Long-Term Debt Repayments was 479.54% (2022), while the steepest drop was 49.62% (2022).
  • Quarterly analysis of 3 years shows InMed Pharmaceuticals' Long-Term Debt Repayments stood at $214,791 in 2021, then tumbled by 49.62% to $108,209 in 2022, then dropped by 12.76% to $94,400 in 2023.
  • Its Long-Term Debt Repayments was $94,400 in Q4 2023, compared to $98,709 in Q3 2023 and $109,085 in Q2 2023.